company background image
SONN

Sonnet BioTherapeutics Holdings NasdaqCM:SONN Stock Report

Last Price

US$0.30

Market Cap

US$18.1m

7D

-1.4%

1Y

-69.4%

Updated

12 Aug, 2022

Data

Company Financials +
SONN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

SONN Stock Overview

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action.

Sonnet BioTherapeutics Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sonnet BioTherapeutics Holdings
Historical stock prices
Current Share PriceUS$0.30
52 Week HighUS$2.07
52 Week LowUS$0.23
Beta0.12
1 Month Change2.44%
3 Month Change15.59%
1 Year Change-69.44%
3 Year Changen/a
5 Year Changen/a
Change since IPO-95.28%

Recent News & Updates

Jul 22

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Sonnet BioTherapeutics (NASDAQ:SONN) said a phase 1b/2a trial of SON-080 was authorized to begin in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is damage to the nerves outside the brain and spinal cord (peripheral nerves) causing weakness and pain, usually in the hands and feet. It can also affect digestion, urination and circulation. Chemotherapy can also cause peripheral nerve damage in patients. SON-080 is a proprietary version of recombinant human Interleukin-6 (rhIL-6), the company noted in a July 22 press release. The study, dubbed SB211, is aimed to provide safety data compared to previous IL-6 products, along with preliminary efficacy. "Interleukin-6 has been extensively studied in cancer patients in the past, so the use of SON-080 in CIPN is expected to provide similar safety, PK, and PD results at low doses," said Sonnet's Chief Medical Officer Richard Kenney. The company noted that recruitment has begun and dosing is expected to begin imminently.

Dec 19
We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

SONNUS BiotechsUS Market
7D-1.4%1.2%1.3%
1Y-69.4%-23.0%-11.7%

Return vs Industry: SONN underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: SONN underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is SONN's price volatile compared to industry and market?
SONN volatility
SONN Average Weekly Movement11.4%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SONN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SONN's weekly volatility has decreased from 20% to 11% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a9Pankaj Mohanhttps://www.sonnetbio.com

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.

Sonnet BioTherapeutics Holdings Fundamentals Summary

How do Sonnet BioTherapeutics Holdings's earnings and revenue compare to its market cap?
SONN fundamental statistics
Market CapUS$18.06m
Earnings (TTM)-US$27.48m
Revenue (TTM)US$708.75k

25.5x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SONN income statement (TTM)
RevenueUS$708.75k
Cost of RevenueUS$19.06m
Gross Profit-US$18.35m
Other ExpensesUS$9.13m
Earnings-US$27.48m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.45
Gross Margin-2,588.95%
Net Profit Margin-3,876.87%
Debt/Equity Ratio0.008%

How did SONN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SONN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SONN?

Other financial metrics that can be useful for relative valuation.

SONN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.3x
Enterprise Value/EBITDA-0.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SONN's PS Ratio compare to its peers?

SONN PS Ratio vs Peers
The above table shows the PS ratio for SONN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.5x
CLSN Celsion
36.6x81.1%US$18.3m
BIOC Biocept
0.3x7.4%US$19.8m
CYTH Cyclo Therapeutics
13.6x67.2%US$19.4m
YMTX Yumanity Therapeutics
3.5xn/aUS$17.9m
SONN Sonnet BioTherapeutics Holdings
25.5x-122.1%US$18.1m

Price-To-Sales vs Peers: SONN is expensive based on its Price-To-Sales Ratio (25.5x) compared to the peer average (13.5x).


Price to Earnings Ratio vs Industry

How does SONN's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: SONN is expensive based on its Price-To-Sales Ratio (25.5x) compared to the US Biotechs industry average (16.5x)


Price to Sales Ratio vs Fair Ratio

What is SONN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SONN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio25.5x
Fair PS Ratio0x

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SONN's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of SONN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SONN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SONN's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Future Growth

How is Sonnet BioTherapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-40.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SONN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SONN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SONN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SONN's revenue is expected to decline over the next 3 years (-122.1% per year).

High Growth Revenue: SONN's revenue is forecast to decline over the next 3 years (-122.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SONN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Sonnet BioTherapeutics Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-41.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SONN is currently unprofitable.

Growing Profit Margin: SONN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SONN is unprofitable, and losses have increased over the past 5 years at a rate of 41.2% per year.

Accelerating Growth: Unable to compare SONN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SONN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).


Return on Equity

High ROE: SONN has a negative Return on Equity (-322%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Sonnet BioTherapeutics Holdings's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SONN's short term assets ($14.9M) exceed its short term liabilities ($6.5M).

Long Term Liabilities: SONN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SONN has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SONN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SONN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SONN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 60.9% each year


Discover healthy companies

Dividend

What is Sonnet BioTherapeutics Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SONN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SONN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SONN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SONN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SONN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Pankaj Mohan (57 yo)

7.58yrs

Tenure

US$792,166

Compensation

Dr. Pankaj Mohan, Ph.D. founded Sonnet BioTherapeutics Holdings, Inc. in 2015 and has since served as a member of its Board of Directors. Dr. Mohan has been Chairman of Sonnet BioTherapeutics Holdings, Inc...


CEO Compensation Analysis

Compensation vs Market: Pankaj's total compensation ($USD792.17K) is about average for companies of similar size in the US market ($USD763.69K).

Compensation vs Earnings: Pankaj's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SONN's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: SONN's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 144.7%.


Top Shareholders

Company Information

Sonnet BioTherapeutics Holdings, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Sonnet BioTherapeutics Holdings, Inc.
  • Ticker: SONN
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$18.055m
  • Shares outstanding: 60.59m
  • Website: https://www.sonnetbio.com

Number of Employees


Location

  • Sonnet BioTherapeutics Holdings, Inc.
  • 100 Overlook Center
  • Suite 102
  • Princeton
  • New Jersey
  • 8540
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/12 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.